No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
PSTX240719C2500
- 0.80
- 0.000.00%
15min DelayClose Jul 16 15:59 ET
0.80High0.80Low
0.80Open0.80Pre Close50 Volume283 Open Interest2.50Strike Price4.00KTurnover0.00%IV-4.90%PremiumJul 19, 2024Expiry Date0.97Intrinsic Value100Multiplier2DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma5.14Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Poseida Therapeutics Announces Participation in Stifel's 2024 Virtual Cell Therapy Forum
SAN DIEGO, July 1, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersAutonomix Medical (NASDAQ:AMIX) shares moved upwards by 11.1% to $1.3 during Tuesday's after-market session. The company's market cap stands at $24.4 million. Unicycive Therapeutics (NASDAQ:UNC
Poseida Therapeutics Announces Virtual 2024 Annual Meeting of Stockholders
SAN DIEGO, June 3, 2024 /PRNewswire/ -- Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated non-viral
H.C. Wainwright Maintains Poseida Therapeutics(PSTX.US) With Buy Rating, Maintains Target Price $20
H.C. Wainwright analyst Arthur He CFA maintains $Poseida Therapeutics(PSTX.US)$ with a buy rating, and maintains the target price at $20.According to TipRanks data, the analyst has a success rate of 5
Analysts Offer Insights on Healthcare Companies: Poseida Therapeutics (PSTX), Greenwich LifeSciences (GLSI) and ACELYRIN, INC. (SLRN)
Express News | Poseida Therapeutics Shares Are Trading Higher After the Company Reported Better-than-expected Q1 Financial Results
Comments
$Poseida Therapeutics(PSTX.US$
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
NEWS
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology
$Poseida Therapeutics(PSTX.US$
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
NEWS
Poseida Therapeutics (PSTX) presents promising data on P-BCMA-ALLO1 for relapsed/refractory multiple myeloma, achieving clinical responses and good tolerability. The study highlights the need for higher lymphodepletion doses in solid tumors. The company continues to innovate in allogeneic CAR-T therapies for cancer treatment.
Dr. Rizvi's appointment, with his vast experience in cancer treatments, is a major asset to Poseida Therapeutics. His expertise will be crucial as the company progresses its clinical stage CAR-T portfolio.
2
Poseida Therapeutics' P/S ratio remains modest despite the recent stock price surge. With inferior revenue forecasts and expected revenue decline, it's unlikely for a significant increase in share price in the near future.
Read more